Bernd Eschgfaeller

Independent Board Member • T-CURX

Bernd is very passionate about providing new and improved treatment options to patients in need. 

He has profound experience in the field of CAR-T therapy development and the commercialization of CAR-T cells. He most recently served as Head Customer Operations for cell & gene therapies at Novartis and was a member of the European cell & gene leadership team launching and commercializing Kymriah®, the first FDA-approved CAR-T cell product. Prior to that, Bernd was leading the cell therapies strategy development for Europe shaping the design of the commercial model for CAR-T provision. 

He helped to bring to market multiple new therapies during his extensive 20-years experience working in Lifesciences in pharma and biotech. He holds a Ph.D. in natural sciences from the ETH Zurich, Switzerland. 

Also speaking

Pedro Silva Couto

Post Doctoral Research Fellow • UCL

Hans S. Keirstead

Chairman of the Board • Immunis

Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Event Info


Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.